As large employers experiment with ways to jump start the use of lower-cost biosimilars among their staff, the former Dean Foods tried a health plan carve-out—on both medical and pharmacy benefit sides—that led to a cost savings of $174,600 (77% reduction) by switching employees on a select number of originator specialty drugs to biosimilars, according to a report.